Details of the Drug Combination

General Information of Drug Combination (ID: DC9T1H5)

Drug Combination Name
Bexarotene Capecitabine
Indication
Disease Entry Status REF
Metastatic Triple-Negative Breast Carcinoma Phase 1 [1]
Component Drugs Bexarotene   DMOBIKY Capecitabine   DMTS85L
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bexarotene
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Approved [2]
Plasma cell myeloma 2A83.1 Approved [3]
Primary cutaneous T-cell lymphoma N.A. Approved [3]
Schizoaffective disorder 6A21 Approved [3]
Bexarotene Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor RXR-alpha (RXRA) TT6PEUO RXRA_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Bexarotene Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Bexarotene Interacts with 86 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Affects Binding [9]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Decreases Expression [10]
Involucrin (IVL) OT4VPNGY INVO_HUMAN Decreases Expression [10]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Decreases Expression [10]
Protein-glutamine gamma-glutamyltransferase K (TGM1) OTB8URRI TGM1_HUMAN Decreases Expression [10]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) OTKOZRZP PLOD2_HUMAN Increases Expression [6]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Expression [6]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [6]
Period circadian protein homolog 2 (PER2) OTU2B1DJ PER2_HUMAN Decreases Expression [6]
Cytochrome P450 26A1 (CYP26A1) OTL1DFWV CP26A_HUMAN Increases Expression [6]
E3 ubiquitin-protein ligase SIAH2 (SIAH2) OTKED2XN SIAH2_HUMAN Decreases Expression [6]
Integral membrane protein 2A (ITM2A) OT590V63 ITM2A_HUMAN Increases Expression [6]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [6]
Short-chain dehydrogenase/reductase 3 (DHRS3) OTSK1DTP DHRS3_HUMAN Increases Expression [6]
PRA1 family protein 3 (ARL6IP5) OTYZ6BEQ PRAF3_HUMAN Increases Expression [6]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Increases Expression [6]
Cytochrome c oxidase subunit 2 (COX2) OTTMVBJJ COX2_HUMAN Decreases Expression [6]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Increases Expression [6]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Expression [6]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [6]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Decreases Expression [6]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [6]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [6]
Pro-cathepsin H (CTSH) OTLFL0DG CATH_HUMAN Increases Expression [6]
Retinoic acid receptor beta (RARB) OT367U3E RARB_HUMAN Increases Expression [6]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Decreases Expression [6]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [6]
Integrin beta-6 (ITGB6) OTI3DJ7U ITB6_HUMAN Increases Expression [6]
Keratin, type I cytoskeletal 15 (KRT15) OTS6WLF7 K1C15_HUMAN Increases Expression [6]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Increases Expression [6]
Insulin-like growth factor-binding protein 6 (IGFBP6) OTW878VI IBP6_HUMAN Increases Expression [6]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Decreases Expression [6]
Ephrin type-A receptor 2 (EPHA2) OTI6QNX2 EPHA2_HUMAN Decreases Expression [6]
Transmembrane 4 L6 family member 1 (TM4SF1) OTY0ECQN T4S1_HUMAN Increases Expression [6]
High affinity cationic amino acid transporter 1 (SLC7A1) OTR2ZVA8 CTR1_HUMAN Decreases Expression [6]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Decreases Expression [6]
Interleukin-15 (IL15) OTQSYWQS IL15_HUMAN Increases Expression [6]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Increases Expression [6]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Decreases Expression [6]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Decreases Expression [6]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Increases Expression [6]
CCAAT/enhancer-binding protein gamma (CEBPG) OTGNAX3H CEBPG_HUMAN Decreases Expression [6]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Decreases Expression [6]
Serine/arginine-rich splicing factor 2 (SRSF2) OTVDHO6U SRSF2_HUMAN Decreases Expression [6]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Decreases Expression [6]
Urokinase plasminogen activator surface receptor (PLAUR) OTIRKKEQ UPAR_HUMAN Decreases Expression [6]
Keratin, type I cytoskeletal 17 (KRT17) OT6Y1DPK K1C17_HUMAN Decreases Expression [6]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Increases Expression [6]
Early growth response protein 3 (EGR3) OTGPJIRA EGR3_HUMAN Decreases Expression [6]
Proline-rich nuclear receptor coactivator 1 (PNRC1) OTQMLEE1 PNRC1_HUMAN Increases Expression [6]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 (BNIP2) OTVZD4H6 BNIP2_HUMAN Decreases Expression [6]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Increases Expression [6]
Krueppel-like factor 10 (KLF10) OT4F4UGS KLF10_HUMAN Decreases Expression [6]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [6]
Inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) OTX7MWW1 ITPR1_HUMAN Increases Expression [6]
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1) OT9EROL6 HERP1_HUMAN Decreases Expression [6]
Adipogenesis regulatory factor (ADIRF) OTTJP8D4 ADIRF_HUMAN Increases Expression [6]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Decreases Expression [6]
TSC22 domain family protein 3 (TSC22D3) OT03UM03 T22D3_HUMAN Increases Expression [6]
Mothers against decapentaplegic homolog 5 (SMAD5) OTQNSVCQ SMAD5_HUMAN Increases Expression [6]
Immediate early response gene 2 protein (IER2) OT5OY8BO IER2_HUMAN Decreases Expression [6]
RNA-binding protein PNO1 (PNO1) OT010GIS PNO1_HUMAN Decreases Expression [6]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [6]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [6]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Increases Expression [6]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Decreases Expression [6]
Angiomotin-like protein 2 (AMOTL2) OTRCTKV9 AMOL2_HUMAN Decreases Expression [6]
Lysyl oxidase homolog 2 (LOXL2) OTRT46B5 LOXL2_HUMAN Increases Expression [6]
Tumor protein p73 (TP73) OT0LUO47 P73_HUMAN Increases Expression [11]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [11]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Increases Expression [12]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [13]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Phosphorylation [14]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [11]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [11]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [15]
Retinoic acid receptor RXR-beta (RXRB) OTNPDXG2 RXRB_HUMAN Affects Binding [9]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Increases Expression [16]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [11]
Retinoic acid receptor RXR-gamma (RXRG) OT254B09 RXRG_HUMAN Affects Binding [9]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Expression [17]
Oxysterols receptor LXR-alpha (NR1H3) OT54YZ9I NR1H3_HUMAN Decreases Expression [16]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Activity [11]
Krueppel-like factor 9 (KLF9) OTBFEJRQ KLF9_HUMAN Increases Expression [18]
Sonic hedgehog protein (SHH) OTOG2BXF SHH_HUMAN Increases Expression [18]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 86 DOT(s)
Indication(s) of Capecitabine
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [4]
Colon adenocarcinoma N.A. Approved [4]
Colorectal cancer 2B91.Z Approved [5]
Metastasis from malignant tumor of colon N.A. Approved [4]
Rectal adenocarcinoma 2B92 Approved [4]
Breast cancer 2C60-2C65 Phase 3 [5]
Colon cancer 2B90.Z Investigative [4]
Gastric cancer 2B72 Investigative [4]
Capecitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Inhibitor [21]
------------------------------------------------------------------------------------
Capecitabine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [22]
Thymidine phosphorylase (TYMP) DE4HCYL TYPH_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
Capecitabine Interacts with 65 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Increases Expression [24]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [25]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Expression [25]
C-C motif chemokine 21 (CCL21) OT7DOXEM CCL21_HUMAN Decreases Expression [19]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Expression [19]
Aquaporin-8 (AQP8) OT99JKME AQP8_HUMAN Increases Expression [19]
Complement C3 (C3) OTCH5GS0 CO3_HUMAN Decreases Expression [19]
HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1) OTC6GISG DQA1_HUMAN Decreases Expression [19]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Secretion [26]
B-lymphocyte antigen CD20 (MS4A1) OTZTVUBX CD20_HUMAN Decreases Expression [19]
Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1) OTGP6GA4 NR4A1_HUMAN Decreases Expression [19]
40-kDa huntingtin-associated protein (F8A1) OTXTQ59R HAP40_HUMAN Decreases Expression [19]
Chloride anion exchanger (SLC26A3) OTBNK2U2 S26A3_HUMAN Increases Expression [19]
Nuclear receptor subfamily 4 group A member 2 (NR4A2) OT3F9IR2 NR4A2_HUMAN Decreases Expression [19]
Potassium-transporting ATPase alpha chain 2 (ATP12A) OTSQSKEK AT12A_HUMAN Increases Expression [19]
Serine/threonine-protein kinase SIK1 (SIK1) OT6FCHME SIK1_HUMAN Decreases Expression [19]
Hemoglobin subunit beta (HBB) OT514IKQ HBB_HUMAN Decreases Expression [19]
Hemoglobin subunit alpha (HBA1) OTW2BQF4 HBA_HUMAN Decreases Expression [19]
Paired box protein Pax-5 (PAX5) OTYBJJWX PAX5_HUMAN Decreases Expression [19]
Endoplasmic reticulum aminopeptidase 2 (ERAP2) OTEMENYF ERAP2_HUMAN Decreases Expression [19]
Fc receptor-like A (FCRLA) OT6MK4M1 FCRLA_HUMAN Decreases Expression [19]
Leucine-rich repeat-containing protein 15 (LRRC15) OTX7JL8H LRC15_HUMAN Decreases Expression [19]
C-C motif chemokine 19 (CCL19) OTQ2UJMH CCL19_HUMAN Decreases Expression [19]
E3 ubiquitin-protein ligase TRIM31 (TRIM31) OT7VW6RP TRI31_HUMAN Increases Expression [19]
Interleukin-1 receptor type 2 (IL1R2) OT0G7E35 IL1R2_HUMAN Increases Response To Substance [20]
Interleukin-17 receptor B (IL17RB) OT0KDNSF I17RB_HUMAN Increases Response To Substance [20]
Glycogen phosphorylase, brain form (PYGB) OT2ZTJT0 PYGB_HUMAN Increases Response To Substance [20]
Calcium and integrin-binding protein 1 (CIB1) OT4BVCRU CIB1_HUMAN Increases Response To Substance [20]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Increases Response To Substance [20]
cAMP-dependent protein kinase catalytic subunit beta (PRKACB) OT6RMDCE KAPCB_HUMAN Decreases Response To Substance [20]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Increases Response To Substance [20]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Decreases Response To Substance [20]
Protein flightless-1 homolog (FLII) OT7G9JG6 FLII_HUMAN Decreases Response To Substance [20]
Stress-induced-phosphoprotein 1 (STIP1) OT7TXLOX STIP1_HUMAN Decreases Response To Substance [20]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Decreases Response To Substance [20]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Response To Substance [20]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Increases Response To Substance [27]
Ras-related protein Rab-40B (RAB40B) OTCA9ZF5 RB40B_HUMAN Increases Response To Substance [20]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Increases Response To Substance [20]
Iron-sulfur clusters transporter ABCB7, mitochondrial (ABCB7) OTDNTHNR ABCB7_HUMAN Decreases Response To Substance [20]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13) OTESFZSO PTN13_HUMAN Decreases Response To Substance [20]
ADP-ribosylation factor-like protein 4D (ARL4D) OTG5I3KU ARL4D_HUMAN Decreases Response To Substance [20]
Double-strand break repair protein MRE11 (MRE11) OTGU8TZM MRE11_HUMAN Decreases Response To Substance [20]
Inorganic pyrophosphatase (PPA1) OTHZK1QB IPYR_HUMAN Increases Response To Substance [20]
Polycystin-2 (PKD2) OTIXBU8H PKD2_HUMAN Decreases Response To Substance [20]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Increases Response To Substance [20]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases Response To Substance [20]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Increases Response To Substance [20]
Plakophilin-2 (PKP2) OTJOVF68 PKP2_HUMAN Increases Response To Substance [20]
Transcriptional enhancer factor TEF-1 (TEAD1) OTK6971C TEAD1_HUMAN Decreases Response To Substance [20]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Decreases Response To Substance [20]
Myelin regulatory factor (MYRF) OTKF6AEB MYRF_HUMAN Increases Response To Substance [20]
Galectin-4 (LGALS4) OTKQCG0H LEG4_HUMAN Increases Response To Substance [20]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Decreases Response To Substance [20]
Hepatoma-derived growth factor-related protein 3 (HDGFL3) OTNN7WYH HDGR3_HUMAN Decreases Response To Substance [20]
E3 ubiquitin-protein ligase TRIM15 (TRIM15) OTNYAKP6 TRI15_HUMAN Increases Response To Substance [20]
Dermatan-sulfate epimerase (DSE) OTQ108VJ DSE_HUMAN Decreases Response To Substance [20]
Anterior gradient protein 2 homolog (AGR2) OTRRZT7W AGR2_HUMAN Increases Response To Substance [20]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Increases Response To Substance [20]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Decreases Response To Substance [20]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Increases Response To Substance [20]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) OTVKRET0 THIK_HUMAN Increases Response To Substance [20]
Tissue alpha-L-fucosidase (FUCA1) OTW71IK4 FUCO_HUMAN Increases Response To Substance [20]
GTPase HRas (HRAS) OTWQN0DP RASH_HUMAN Decreases Response To Substance [20]
Epidermal growth factor receptor kinase substrate 8 (EPS8) OTZ6ES6V EPS8_HUMAN Increases Response To Substance [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 65 DOT(s)

References

1 ClinicalTrials.gov (NCT04664829) The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807).
3 Bexarotene FDA Label
4 Capecitabine FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
6 Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
9 Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
10 Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ. 1996 Aug;7(8):997-1004.
11 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
12 Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996 Jul;16(7):3350-60. doi: 10.1128/MCB.16.7.3350.
13 Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol. 2005 Mar;141(3):315-21. doi: 10.1001/archderm.141.3.315.
14 Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar;96(2):147-57. doi: 10.1007/s10549-005-9071-1. Epub 2005 Nov 5.
15 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
16 Combinations of LXR and RXR agonists induce triglyceride accumulation in human HepaRG cells in a synergistic manner. Arch Toxicol. 2020 Apr;94(4):1303-1320. doi: 10.1007/s00204-020-02685-7. Epub 2020 Mar 2.
17 Tributyltin and triphenyltin induce 11-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor . Toxicol Lett. 2020 Apr 1;322:39-49. doi: 10.1016/j.toxlet.2020.01.001. Epub 2020 Jan 9.
18 Pituitary specific retinoid-X receptor ligand interactions with thyroid hormone receptor signaling revealed by high throughput reporter and endogenous gene responses. Toxicol In Vitro. 2015 Oct;29(7):1609-18. doi: 10.1016/j.tiv.2015.06.018. Epub 2015 Jun 19.
19 Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022 Dec 1;371:17-24. doi: 10.1016/j.toxlet.2022.09.013. Epub 2022 Sep 29.
20 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
21 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
22 Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.
23 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
24 DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol. 2007 Aug;31(2):413-8.
25 Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. Biomed Pharmacother. 2007 Oct;61(9):596-600.
26 P38 MAPK, NF-B, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression. Chem Res Toxicol. 2022 Mar 21;35(3):422-430. doi: 10.1021/acs.chemrestox.1c00317. Epub 2022 Feb 11.
27 A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab. 2008 May;9(4):336-43. doi: 10.2174/138920008784220646.